Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14;16(1):272.
doi: 10.1186/s13098-024-01514-6.

Simvastatin reduces chronic kidney disease and renal failure risk in type 2 diabetes patients: post hoc ACCORD trial analysis

Jiaxi Pu  1 , Ming Gao  2 , Pan Yu  1 , Jiaqi Tian  3 , Junxia Yan  4 , Qiongjing Yuan  1 , Lijian Tao  1 , Zhangzhe Peng  5
Affiliations

Simvastatin reduces chronic kidney disease and renal failure risk in type 2 diabetes patients: post hoc ACCORD trial analysis

Jiaxi Pu et al. Diabetol Metab Syndr. .

Abstract

Objective: Type 2 diabetes mellitus (T2DM) poses a substantial global health concern. Statins are widely used among T2DM patients for managing dyslipidemia, preventing cardiovascular disease (CVD), and offering renal protection. However, the extent to which their renal protective effects contribute to reducing the incidence of severe renal complications, including chronic kidney disease (CKD) and renal failure, is not well-defined.

Methods: This investigation scrutinizes the impact of simvastatin versus placebo on renal outcomes among T2DM patients utilizing data from the ACCORD trial. It encompasses incidence rate comparisons, Kaplan-Meier estimates, Cox proportional hazards models, and mediation analyses.

Results: The study consisted of 3,619 individuals diagnosed with T2DM, among which 2,753 were treated routinely with simvastatin, while 866 did not receive any statin therapy. After adjusting for baseline characteristics and time-dependent covariates, simvastatin treatment was associated with a 71% reduction in the risk of CKD (HR 0.29, 95% CI 0.27-0.31, p < 0.01) and a 47% reduction in the risk of renal failure (HR 0.53, 95% CI 0.44-0.65, p < 0.01) compared to the statin-free group. Further subgroup analysis, accounting for the initial lipid and kidney profiles, indicated variable impacts of simvastatin on CKD and renal failure outcomes. Nevertheless, a consistent reduction in CKD risk was observed across all subgroups within the statin-treated population. Additional mediation analysis revealed that the reduction in low-density lipoprotein cholesterol (LDL-C) may be a potential mediator in the association between simvastatin and CKD, with a mediation effect of 14.9%, (95% CI 0.11-0.19, p < 0.01).

Conclusion: Administering statins, specifically simvastatin, to T2DM patients at elevated risk for CVD, is likely to offer augmented renal advantages, notably in lowering the occurrence of CKD and renal failure. This protective effect against CKD manifests regardless of initial lipid profiles, albuminuria, and estimated glomerular filtration rate (eGFR) levels. The association between simvastatin and CKD may be partially mediated by LDL-C reduction.

Keywords: ACCORD; Chronic kidney disease; Renal failure; Simvastatin; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval and consent to participate This investigation received approval from Xiangya Hospital, Central South University (Study number 202210011) and conducted according to the Declaration of Helsinki. Participants had previously given informed consent for the whole project [8]. Consent for publication All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, and have given their approval for this version to be published. Competing interests The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study profile
Fig. 2
Fig. 2
Cumulative incidence of primary outcomes for patients with and without simvastatin treatment. (A) chronic kidney disease; (B) renal failure
Fig. 3
Fig. 3
Treatment effects of simvastatin versus placebo on chronic kidney disease in subgroups
See this image and copyright information in PMC

References

    1. Stadler K, Goldberg IJ, Susztak K. The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep. 2015;15(7):40. - PMC - PubMed
    1. Libby P, et al. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104(2A):S14–8. - PubMed
    1. Silverman MG, et al. Association between lowering LDL-C and Cardiovascular Risk Reduction among different therapeutic interventions: a systematic review and Meta-analysis. JAMA. 2016;316(12):1289–97. - PubMed
    1. American Diabetes Association Professional Practice. 10. Cardiovascular Disease and Risk Management: standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–74. - PubMed
    1. Su X, et al. Effect of statins on kidney Disease outcomes: a systematic review and Meta-analysis. Am J Kidney Dis. 2016;67(6):881–92. - PubMed

LinkOut - more resources